NDH.com

icon


Wolters Kluwer | Lippencott Williams & Wilkins
Drug Warnings
orange bar


   Web Toolkit
   Drug Updates

   Patient Teaching

   News Capsules

   Drug Warnings

   Herbal Spotlight

   Nursing Links

   CE

   Career Opportunities

   Drug Info Bookstore

   Feedback

   Registration

   Disclaimer



bisphosphonates
Actonel, Aredia, Boniva, Didronel, Fosamax, Reclast, Skelid, Zometa
 

NEW WARNING
The FDA issued an alert to healthcare providers about the possibility of severe and sometimes incapacitating bone, joint, or muscle pain in patients taking bisphosphonates (including Actonel, Aredia, Boniva, Didronel, Fosamax, Reclast, Skelid, Zometa). Pain occurring within days, months, or years of starting the bisphosphonate have been reported. This is in contrast to the reported acute phase response (fever, chills, bone pain, myalgia, and arthralgia), which occurs after initial administration of I.V. bisphosphonate, and sometimes with initial use of the weekly or monthly preparations. These symptoms usually resolve within days of discontinuing the drug. Providers are advised to be aware of this possibility, teach patients to report the occurrence of such pain, and to weigh the benefits and risks of bisphosphonate therapy in patients who experience this reaction.

     
   

Home - Guest Registry - Customer Service

Brought to you by Lippincott Williams & Wilkins.
For help on how you should use this site, see our
Disclaimer .

© Copyright 2008 by Lippincott Williams & Wilkins